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Abstract
Nerve grafts are used to repair segmental defects in peripheral nerves. However, autografts 
and even allografts are limited for clinical use. Xenotransplantation offers a potentially 
unlimited source for tissue transplantation. We have conducted a systematic review of 
the literature, aiming to clarify the latest and more appealing proposals and discoveries in 
nerve xenotransplantation. A total of 22 articles were retrieved, all of them experimentally 
controlled studies in animals. There are no current studies in humans. Fresh xenografts 
provoke an immune response that leads to graft rejection. Immunosuppressive drugs or 
pretreatment of the grafts are the preferred methods against immune rejection. Recently, 
investigative groups have proposed the use of acellular nerve xenografts, which do not 
elicit immune rejection while they do allow and promote axonal regeneration. The addition 
of human stem cells increases nerve growth. Limits to the analyzed studies are the absence 
of trials in humans and the short length of the nerve defects that have been successfully 
repaired. Further investigations and clinical trials are needed before nerve xenografting is 
accepted as a valid method of nerve repair.
Keywords: heterologous transplantation, immune tolerance, nerve repair, peripheral 
nerves, stem cells, xenografts
1. Introduction
Nerve grafts are used to bridge defects in peripheral nerves that cannot be repaired by direct 
suturing. However, autografts and even allografts are limited for clinical use. The ready avail‐
ability of xenografts has put them in the center of clinical surgery research as an alternative 
graft strategy.
Xenotransplantation offers a potentially unlimited source for tissue transplantation, but with 
the obvious drawback of immune rejection. Many groups are investigating the molecular, 
immunologic, biologic, and cellular aspects of xenotransplantation and have proposed various 
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techniques and approaches to perfect the composition of the transplanted tissue and to module 
the immune response, in an attempt to find the perfect nerve xenograft.
We have conducted a systematic review of the literature, aiming to clarify the latest and more 
appealing proposals and discoveries in nerve xenotransplantation, which we detail in the 
following text.
2. Systematic review
We searched PubMed and Embase databases, using the combined search terms “xenotrans‐
plantation” or “heterologous transplantation” and “peripheral nerve.” We screened titles and 
abstracts and decided which articles to retrieve. Articles were also identified by a manual search 
of bibliographies from all retrieved articles. Studies were eligible for inclusion if they addressed 
both heterologous transplantation and peripheral nervous system. Only articles with English 
language abstracts were included. For those articles that were not available in English, only 
the content of the abstracts was analyzed. Excluded studies were those addressing the central 
nervous system. No limits were placed on publication date or study design.
3. Results
A total of 22 articles were retrieved, all of them experimentally controlled studies in animals. 
Most studies used rats as host species [1–15]. Four studies used mice [16–19]. The most com‐
monly used nerve for the nerve defect was the sciatic nerve [2, 3, 5, 8–10, 12–19]. As for donor 
species, New Zealand rabbits [1, 3, 6, 12] and Sprague‐Dawley rats [16–19] were the most 
commonly used. One study compared the outcomes using different species [9]. One study 
used human nerves (sural nerve) [9]. Six studies used human mesenchymal stem cells laden 
in autologous or synthetic conduits [8, 10, 13–15, 20]. There have been no studies with humans 
as recipients for xenografts.
Table 1 shows the details of the species and nerve defects used in each study.
Sample size ranged from 6 to 96. Follow‐up time ranged from 2 to 360 days. Table 2 shows 
details of the sample size, follow‐up time, and type of graft used.
3.1. Type of graft
Of the 22 retrieved articles, 7 described a study in which nerve defects were repaired with 
fresh nerve xenografts [4, 7, 16–19]. Six studies used acellular nerve xenografts [1–3, 6, 9]. Two 
used both fresh xenografts and acellular xenografts [11, 12]. Six studies used biological or 
synthetic conduits seeded with xenogeneic cells [8, 10, 13–15, 20]. One of the articles does not 
specify the type of graft used [21].
Among the studies that used acellular nerve xenografts, different extraction procedures were 
used. Two studies compare results with the extraction procedure as a variable [9,12].
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In general, the consensus is that fresh xenografts provoke an immune response [5, 16–18] 
that leads to graft rejection [7, 11, 12, 19]. Choi and Raisman [4] conclude that in short nerve 
gaps of 7–8 mm, regeneration can occur in spite of the immune rejection, without the need for 
immunosuppressant drugs, but longer defects of 15–20 mm require immunosuppression to 
Reference Host Donor Gap (mm)
1 Hebebrand et al. [5] Lewis rat (sciatic n) Golden Syrian hamster (sciatic n) 5
2 Hebebrand et al. [21] ? ? ?
3 De Vaconcellos et al. 
[11]
Sprague‐Dawley rat  
(median n)
Beagles dog (antebrachial  
cutaneous n)
10
4 Li et al. [12] Sprague‐Dawley rat  
(sciatic n)
Rabbit (tibial n) 15
5 Udina et al. [19] OF1 mouse (sciatic n) Sprague‐Dawley rat (peroneal n) 6
6 Choi and Raisman [4] AS strain rat (facial n) Balb‐C mouse (sciatic n) 7–8 versus 15–20
7 Lu et al. [7] Sprague‐Dawley rat 
(peroneal n)
Balb‐C mouse (sciatic n) 10
8 Zhang et al. [2] Sprague‐Dawley rat  
(sciatic n)
York pig (intercostal n) 10
9 Kvist et al. [9] Wistar rat (sciatic n) Frog Rana temporaria, NRMI mouse 
(sciatic n), human (sural n), pig 
Suidae Yorkshire (tibial n)
7
10 Jia et al. [3] Wistar rat (sciatic n) New Zealand rabbit (?) 10
11 Yu et al. [16] Balb‐C mouse (sciatic n) Sprague‐Dawley rat (sciatic n) 5
12 Huang et al. [22] Rhesus monkey (radial n) Landrace pig (tibial n) 25
13 Zhu and Lou [1] Wistar rat (facial n) New Zealand rabbit (facial n) 6
14 Sakar et al. [14] Sprague‐Dawley rat  
(sciatic n)
Human cells 10
15 Gärtner et al. [13] Sprague‐Dawley rat  
(sciatic n)
Human cells –
16 Chai et al. [18] C57 BL6 mouse (sciatic n) Sprague‐Dawley rat (sciatic n) 20
17 Tremp et al. [8] Sprague‐Dawley rat  
(sciatic n)
Human cells 10
18 Huang et al. [6] Wistar rat (facial n) New Zealand white rabbit (facial n) 10
19 Lasso et al. [20] New Zealand rabbit 
(peroneal n)
Human cells 40
20 Zarbakhsh et al. [10] Wistar rat (sciatic n) Human cells 10
21 Yu et al. [17] Balb‐C mouse (sciatic n) Sprague‐Dawley rat (sciatic n) 5
22 Masgutov et al. [15] Rat (sciatic n) Human cells 10
Table 1. Detail of the species and nerve defects used in each study.
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Reference Sample Follow up (days) Type xenograft
1 Hebebrand et al. [5] ? ? Fresh xenograft ± FK506/RS61443
2 Hebebrand et al. [21] ? ? ?
3 De Vaconcellos et al. [11] 60 360 ANX versus fresh xenograft
4 Li et al. [12] 30 180 ANX versus fresh xenograft
5 Udina et al. [19] 35 21 Fresh xenograft ± FK506
6 Choi and Raisman [4] 96 84 Fresh xenograft ± cyclosporine
7 Lu et al. [7] 30(?) 56 Fresh xenograft
8 Zhang et al. [2] 6 90 AXN + autoADSC
9 Kvist et al. [9] 53 10 ANX
10 Jia et al. [3] 50 56 ANX + BMSC
11 Yu et al. [16] 48 (?) 30 Fresh xenograft
12 Huang et al. [22] 10 150 ANX + autoADSC
13 Zhu and Lou [1] 40 140 ANX
14 Sakar et al. [14] 27 56 hMSC
15 Gärtner et al. [13] 140 hUCSC
16 Chai et al. [18] 200(?) 28 Fresh xenograft
17 Tremp et al. [8] 13 28 Fibrin conduit + hADSC or hSVF
18 Huang et al. [6] 18 84 ANX
19 Lasso et al. [20] 60 90 Vein graft ± Cyclosporine ± hADSC
20 Zarbakhsh et al. [10] 24 84 Silicone conduit ± autoBMSC ± hUCSC
21 Yu et al. [17] ? 3 Fresh xenograft + BDNF
22 Masgutov et al. [15] 29 65 hADSC
ANX, acellular nerve xenograft; hADSC, human adipose‐derived stem cells; ADSC, adipose‐derived stem cells; BMSC, 
bone marrow stem cells; BDNF, brain‐derived neurotrophic factor; hSVF, human stromal vascular fraction; hUCSC, 
human umbilical cord stem cells; hMSC, human mesenchymal stem cells.
Table 2. Detail of sample size, follow‐up time, and type of graft used.
achieve nerve growth. Acellular nerve xenografts do not elicit an immune response [22] and 
can therefore be used to bridge nerve defects without immunosuppressant drugs with good 
results [1–3, 6, 9, 11, 12, 22].
Nerve conduits are useful for nerve restoration. Xenogeneic stem cell‐laden conduits prove an 
increased regenerative ability [8, 10, 13–15, 20].
3.2. Immunosuppression
There is a total of four studies that compare the outcomes with or without the use of immuno‐
suppressive drugs (two use Cyclosporine A, two use FK506) [4, 5, 19, 20]. Immunosuppressant 
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treatment with cyclosporine A, FK506, or RS61443 can reduce acute graft rejection and allow 
nerve regeneration [4, 5, 19].
Two studies propose that specific antibodies against interleukins could also be useful in 
decreasing graft rejection[16, 18].
Among the studies that use xenogeneic cells only, one compares outcomes with and with‐
out immunosuppressive therapy [20]. Tremp et al. [8] and Zarbakhsh et al. [10] suggest that 
human stem cells act as immunosuppressants, with an ability to induce the production of 
anti‐inflammatory cytokines, and they therefore do not use immunosuppressive drugs.
3.3. Defect length
The nerve defect ranged from 5 to 25 mm in the studies that used xenografts and up to 40 mm 
in one study that used vein grafts laden with human adipose‐derived stem cells (hADSC) [2].
The length of the gap that has been successfully bridged is 7–8 mm with unprocessed xeno‐
grafts [4], 25 mm with acellular nerve grafts [5], and 40 mm with vein conduits seeded with 
hADSC [20]. The consensus is that only short gaps can reach complete regeneration with a 
xenograft, and further studies are required to find a viable conduit that bridges longer nerve 
gaps with a tolerable immune response.
4. Discussion
Nerve grafting was first reported by Philipeaux and Vulpian in 1870. The first human nerve 
graft was reported by Albert in 1878. For decades, research has advanced in favor of auto‐
grafts, with progress being made in the understanding of nerve biology and chemical mech‐
anisms involved in nerve repair and the perfecting of suture and surgical techniques. But 
although autologous nerve grafting is ideal, it has some obvious disadvantages, such as 
lack of availability and donor‐site morbidity. For this reason, investigations turned to nerve 
allografts. Attempts to reduce the rejection of nerve allografts have focused on either nerve 
graft pretreatment or host immunosuppression [23–25]. The results have not reached those 
of autografting, and even allografts are a limited source. The ready availability of xenografts 
has recently put them in the center of clinical surgery research as an alternative graft strategy.
Much of the current research is focused on the study of host immune response to xenografts, 
as well as the genetics and biochemical reactions involved in graft integration. The immune 
response to nerve xenotransplantation is poorly understood; most of the research is based on 
the existing knowledge of nerve allografts.
Peripheral nerves are composed of nerve axons, fibroblasts, Schwann cells, and extracellular 
matrix. Host Schwann cells are critical for nerve regeneration and production of neurotrophic 
factors and, Schwann cells of long nerve grafts are also involved in the regenerative process [26]. 
But donor Schwann cells are one of the most immunogenic components of nerve allografts [27, 
28] and it is immune rejection and the scar tissue that is formed due to the immune response 
that inhibits axon regeneration [29]. To reduce this reaction, allografts have been pretreated to 
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decrease their antigenicity, but these treatments also reduce Schwann cell viability [30]. Recent 
studies are moving away from nerve graft pretreatment and toward investigating other mech‐
anisms of immune response suppression.
Lu et al. [7] described the importance of cellular immune responses in xenograft rejection. 
They also described the limitations in xenografting of cold preservation of the grafts as a way 
to decrease rejection, a method frequently used in allografting.
Of the same group, Yu et al. [16] proved that xenograft rejection is mediated especially 
by interferon‐gamma (IFγ)‐producing Th1 cells and IL17‐producing Th17 cells. They sug‐
gested that the rejection of a xenograft can be prevented after treatment with IL17 and 
IFγ‐neutralizing antibodies. In a recent study [17], they proposed brain‐derived neuro‐
trophic factor as a promising inhibitor of peripheral nerve xenograft rejection. Chai et al. 
[18] studied the significance of Th22 and Treg cells interaction in the regulation of xenograft 
rejection.
Based on these studies of immune response, trials have been made using different types of 
immunosuppressive drugs. Choi and Raisman [4] propose that there is a limit distance that 
nerve regeneration through a xenograft is able to cover against acute host rejection, but to 
grow further it requires the assistance of immunosuppression (their experiments are carried 
out on facial nerve grafts from mouse to rat).
Hebebrand [5, 21] proved increased nerve regeneration through xenografts with immunosup‐
pression with FK506 and RS61443 based on the knowledge that they have on neuroregenera‐
tive and neuroprotective effects independent of their immunosuppressive activity. Udina et 
al. [19] proved that a 5‐mg/kg/day dose of FK506 is necessary to achieve nerve regeneration in 
rat to mice xenografts, as opposed to a 2‐mg/kg/day dose for allografts.
There are no clinical studies in humans. Magnusson et al. [31] proposed to begin the study of pig 
to human xenotransplantation by describing the xenoantigenic pattern on porcine peripheral 
nerve.
A different line of research regarding peripheral nerve repair has focused on the application 
of biologic or synthetic nerve conduits [32]. Donor‐site morbidity is reduced, as is surgery 
time, and the problem of rejection is avoided. The ideal properties of a nerve conduit are 
biocompatibility, biodegradability, neuroinductivity, and neuroconductivity. The last two 
properties can be enhanced by adding host or xenogeneic multipotent stem cells with the 
ability to produce the necessary growth factors. Bone marrow stromal cells (BMSCs), human 
umbilical cord stromal cells (HUCSCs), undifferentiated, and adipose‐derived stem cells have 
been studied, with different results [8, 10, 13–15, 20, 33]. Zarbakhsh et al. [10] conducted a 
study with 24 Wistar rats, where 10‐mm gaps in the sciatic nerve were bridged with a silicone 
conduit with added bone marrow stromal cells, human umbilical cord stromal cells or no 
cells. He concluded that both auto‐BMSCs and xeno‐UCSC have the potential to regenerate 
peripheral nerve injury and that BMSCs are more effective than HCUCSCs in rat. As opposed 
to other xenogeneic cells, stem cells did not seem to provoke an immune response in the host 
after transplantation [34, 35].
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Silicone or fibrin scaffolds, or even veins, only provide a physical conduit for nerve regeneration. 
But the goal is to provide a conduit that is also able to produce the adequate molecular signals 
that promote cell differentiation, migration, and axonal elongation. This can only be achieved 
using peripheral nerves as nerve grafts. Therefore, the aim of investigators has been to find or 
create a non‐immunogenic xenograft. Acellular xenografts are created chemically eliminating 
the cellular constituents that cause immunogenic reactions but preserving the native extracel‐
lular matrix, which retains sufficient bioactivity to promote axon regeneration [36].
Huang et al. [22] used acellular xenografts with allogenic adipose‐derived stem cells in rhesus 
monkey, obtaining no immune response to the grafts. They later conducted a study in rat 
facial nerve defects, achieving similar results to those obtained with allografts [6]. Similar 
results were reported by Zhu et al. [1].
In 2010, Zhang et al. [2] reported that acellular nerve xenografts, similar to acellular nerve 
allografts (ANAs), are immunocompatible. He also proposed that short defects can regener‐
ate along acellular scaffolds but that longer defects might require certain cellular impulses, 
which should be provided by added autologous stem cells.
Li et al. [12] repaired rat sciatic nerve gaps with acellular xenogeneic scaffolds, with good 
results.
Jia et al. [3] transplanted acellular nerve allografts and rabbit xenografts (ANX), with and 
without BMSC enhancement, into rat sciatic nerve gaps, comparing the different groups with 
autografts. They concluded that ANX implanted with BMSCs had a functional rehabilitation 
efficacy comparable to autografting.
De Vaconcellos et al. [11] repaired 2 cm median nerve gaps in rats with Beagle dog acellular 
frozen xenografts, managing a correct but slow regeneration, and thus suggesting that freez‐
ing suppresses the immune reaction but produces a deficient environment.
Kvist et al. [9] studied the differences in acellular xenografts from different species (frog, mice, 
human, and pig) transplanted into rat sciatic nerve gaps, proposing differences in axonal out‐
growth which should be further studied before clinical use.
All existing studies have a clear limitation regarding the species in which the experiments are 
carried out on. No studies used humans as hosts, and only one study included human sural 
nerves as donor for xenografting. Unlike organ transplantation, peripheral nerve grafting 
does not usually occur in a scenario of urgency, and nerve injury is not life‐threatening. Thus, 
nerve xenografts can only be considered in real clinical situations when benefits are heavier 
than the risks associated to immunosuppression and even cross‐species disease transmission.
The future moves toward a xenograft that is immunocompatible—probably acellular, 
seeded with xenogeneic stem cells or similar growth factor‐producing elements—with no 
need of immunosuppressive therapy. Also, advance has to be made in the way of creating 
longer grafts or ways to make the process of regeneration occur fast enough to achieve a 
complete axonal growth in longer defects before scarring and inflammation block nerve 
advancement.
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5. Conclusions
Most of the existing studies on nerve xenografting concur in their results of peripheral nerve 
xenotransplantation, which are found to be similar to those reached with nerve allografts 
and acceptable, though lower, compared to the results of autografting. The scenario in which 
these results can be reached are in all cases similar, defects of 5–25 mm in peripheral nerves, 
of rats or rabbits mostly, repaired with either fresh xenografts—supplemented with immu‐
nosuppressive therapy—or acellular grafts. The direction in which all investigations move is 
toward adding stem cells or other sources of growth factors that might improve the reach of 
axonal growth. A long way still separates us from creating a graft that will work in humans.
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